SciClone Pharmaceuticals Overview
- Year Founded
-
1990
- Status
-
Private
- Employees
-
1,046
- Latest Deal Type
-
Fund - Cont Trans
- Financing Rounds
-
9
- Investments
-
2
SciClone Pharmaceuticals General Information
Description
SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, including oncology and severe infection. Its products are Zadaxin, Zometa, Oravig, Endoxan, Angiomax, and others. It derives revenue from sales of products.
Contact Information
Website
www.sciclone.comCorporate Office
- 22F, Central Plaza
- 381 Middle Huaihai Road
- Shanghai
- China
Corporate Office
- 22F, Central Plaza
- 381 Middle Huaihai Road
- Shanghai
- China
SciClone Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
SciClone Pharmaceuticals Comparisons
Industry
Financing
Details
SciClone Pharmaceuticals Competitors (29)
One of SciClone Pharmaceuticals’s 29 competitors is VBI Vaccines, a Corporation company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| VBI Vaccines | Corporation | Cambridge, MA | ||||
| Precigen | Formerly VC-backed | Germantown, MD | ||||
| ImmunityBio | Formerly VC-backed | San Diego, CA | ||||
| Dynavax Technologies | Formerly VC-backed | Emeryville, CA | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ |
SciClone Pharmaceuticals Signals
SciClone Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
SciClone Pharmaceuticals Investments & Acquisitions (2)
SciClone Pharmaceuticals’s most recent deal was a Later Stage VC with Tarveda Therapeutics for . The deal was made on 27-Sep-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tarveda Therapeutics | 27-Sep-2021 | Later Stage VC | Drug Discovery | ||
| NovaMed Pharmaceuticals | 19-Apr-2011 | Merger/Acquisition | Distributors (Healthcare) |
SciClone Pharmaceuticals Exits (1)
SciClone Pharmaceuticals’s most recent exit was on 27-Sep-2021 from Tarveda Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Tarveda Therapeutics | 27-Sep-2021 | Completed |
|
SciClone Pharmaceuticals FAQs
-
When was SciClone Pharmaceuticals founded?
SciClone Pharmaceuticals was founded in 1990.
-
Where is SciClone Pharmaceuticals headquartered?
SciClone Pharmaceuticals is headquartered in Shanghai, China.
-
What is the size of SciClone Pharmaceuticals?
SciClone Pharmaceuticals has 1,046 total employees.
-
What industry is SciClone Pharmaceuticals in?
SciClone Pharmaceuticals’s primary industry is Drug Discovery.
-
Is SciClone Pharmaceuticals a private or public company?
SciClone Pharmaceuticals is a Private company.
-
What is SciClone Pharmaceuticals’s current revenue?
The current revenue for SciClone Pharmaceuticals is .
-
How much funding has SciClone Pharmaceuticals raised over time?
SciClone Pharmaceuticals has raised $281M.
-
Who are SciClone Pharmaceuticals’s investors?
Bosera Capital, Bradbury Asset Management, China Post Fund, IDG Capital, and Shanghai Dazhong Public Utilities Group are 5 of 10 investors who have invested in SciClone Pharmaceuticals.
-
Who are SciClone Pharmaceuticals’s competitors?
VBI Vaccines, Precigen, ImmunityBio, Dynavax Technologies, and Bristol-Myers Squibb are some of the 29 competitors of SciClone Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process